- Home
- ADCT vs NMAI Comparison
ADCT vs NMAI Comparison
Compare ADCT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADCT | NMAI |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.4M | 461.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADCT | NMAI |
|---|---|---|
| Price | $4.11 | $13.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 812.5K | 107.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 44.90 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $70,837,000.00 | N/A |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $1.06 | N/A |
| P/E Ratio | ★ N/A | $20.66 |
| Revenue Growth | ★ 1.84 | N/A |
| 52 Week Low | $1.05 | $10.21 |
| 52 Week High | $4.80 | $13.96 |
Technical Indicators
Market Signals| Indicator | ADCT | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 31.37 |
| Support Level | $3.25 | $12.72 |
| Resistance Level | $4.71 | $13.05 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 29.76 | 6.82 |
Price Performance
Historical ComparisonAbout ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.